Federico Massa1, Diego Franciotta2, Stefano Grisanti3, Luca Roccatagliata4,5, Silvia Morbelli4,5, Sabrina Beltramini6, Antonio Uccelli3,4, Angelo Schenone3,4, Luana Benedetti3,4. 1. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Largo Daneo 3, 16132, Genoa, Italy. fedemassa88@gmail.com. 2. Autoimmunology Laboratory, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. 3. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Largo Daneo 3, 16132, Genoa, Italy. 4. IRCCS Ospedale Policlinico San Martino, Genoa, Italy. 5. Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy. 6. Pharmacy Complex Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Abstract
BACKGROUND: The immunotherapy strategy for autoimmune encephalitis is based on several types and schedules of both first- and second-line drugs. Failing to respond to the latter prompts the use of non-conventional rescue therapies, with higher risks of severe adverse effects. We report on a protocol that entails the use of intravenous immunoglobulin cycles to bridge the 4-month period that the second-line drug rituximab needs to exert its full therapeutic effects. METHODS: Three patients with NMDAR encephalitis who were non-responders to first-line treatments entered the study. The protocol consisted of six monthly cycles of intravenous immunoglobulins (IVIG, 0.4 mg/kg/die for 5 days), starting 1 month after the last rituximab infusion (1000 mg at days 0 and 15). Brain MRI and [18F]-FDG-PET were performed at onset and at six and 18 months after onset. RESULTS: In the three patients, substantial improvements of disability or complete recovery were achieved, without modifications over the 30-to-50-month follow-up. No adverse events nor laboratory test abnormalities were recorded. Imaging findings paralleled the favorable disease courses. Brain [18F]-FDG-PET was more sensitive than MRI in detecting abnormalities. DISCUSSION: Our observations suggest that the herein-described protocol might be used in patients with NMDAR encephalitis at risk for poor prognosis in the mid-term when they need to shift to rituximab. [18F]-FDG-PET confirmed to be a sensitive tool to detect the minimal brain lesions that can underlie isolated cognitive and psychiatric symptoms.
BACKGROUND: The immunotherapy strategy for autoimmune encephalitis is based on several types and schedules of both first- and second-line drugs. Failing to respond to the latter prompts the use of non-conventional rescue therapies, with higher risks of severe adverse effects. We report on a protocol that entails the use of intravenous immunoglobulin cycles to bridge the 4-month period that the second-line drug rituximab needs to exert its full therapeutic effects. METHODS: Three patients with NMDAR encephalitis who were non-responders to first-line treatments entered the study. The protocol consisted of six monthly cycles of intravenous immunoglobulins (IVIG, 0.4 mg/kg/die for 5 days), starting 1 month after the last rituximab infusion (1000 mg at days 0 and 15). Brain MRI and [18F]-FDG-PET were performed at onset and at six and 18 months after onset. RESULTS: In the three patients, substantial improvements of disability or complete recovery were achieved, without modifications over the 30-to-50-month follow-up. No adverse events nor laboratory test abnormalities were recorded. Imaging findings paralleled the favorable disease courses. Brain [18F]-FDG-PET was more sensitive than MRI in detecting abnormalities. DISCUSSION: Our observations suggest that the herein-described protocol might be used in patients with NMDAR encephalitis at risk for poor prognosis in the mid-term when they need to shift to rituximab. [18F]-FDG-PET confirmed to be a sensitive tool to detect the minimal brain lesions that can underlie isolated cognitive and psychiatric symptoms.
Authors: Franziska S Thaler; Luise Zimmermann; Stefan Kammermeier; Christine Strippel; Marius Ringelstein; Andrea Kraft; Kurt-Wolfram Sühs; Jonathan Wickel; Christian Geis; Robert Markewitz; Christian Urbanek; Claudia Sommer; Kathrin Doppler; Loana Penner; Jan Lewerenz; Rosa Rößling; Carsten Finke; Harald Prüss; Nico Melzer; Klaus-Peter Wandinger; Frank Leypoldt; Tania Kümpfel Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-10-01
Authors: Francesc Graus; Maarten J Titulaer; Ramani Balu; Susanne Benseler; Christian G Bien; Tania Cellucci; Irene Cortese; Russell C Dale; Jeffrey M Gelfand; Michael Geschwind; Carol A Glaser; Jerome Honnorat; Romana Höftberger; Takahiro Iizuka; Sarosh R Irani; Eric Lancaster; Frank Leypoldt; Harald Prüss; Alexander Rae-Grant; Markus Reindl; Myrna R Rosenfeld; Kevin Rostásy; Albert Saiz; Arun Venkatesan; Angela Vincent; Klaus-Peter Wandinger; Patrick Waters; Josep Dalmau Journal: Lancet Neurol Date: 2016-02-20 Impact factor: 44.182
Authors: Hesham Abboud; John C Probasco; Sarosh Irani; Beau Ances; David R Benavides; Michael Bradshaw; Paulo Pereira Christo; Russell C Dale; Mireya Fernandez-Fournier; Eoin P Flanagan; Avi Gadoth; Pravin George; Elena Grebenciucova; Adham Jammoul; Soon-Tae Lee; Yuebing Li; Marcelo Matiello; Anne Marie Morse; Alexander Rae-Grant; Galeno Rojas; Ian Rossman; Sarah Schmitt; Arun Venkatesan; Steven Vernino; Sean J Pittock; Maarten J Titulaer Journal: J Neurol Neurosurg Psychiatry Date: 2021-03-01 Impact factor: 10.154